Noveome Biotherapeutics, Inc. Announces Christopher J. P. Velis as Chief Executive Officer
- Appointment is Effective May 24, 2021
- Mr. Velis will continue his role on Noveome’s Board of Directors
- William J. Golden steps down as CEO, remains as Founder and Chairman of the Board of Directors
PITTSBURGH–(BUSINESS WIRE)–Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has announced that Christopher J. P. Velis has joined the Company as Chief Executive Officer. Mr. Velis was appointed to the Company’s Board of Directors in March 2021.
“We are thrilled to have Chris take on this additional role as our new CEO. His vast experience in innovative medical technologies will help guide Noveome as it continues to develop and commercialize its novel platform biologic, ST266,” said William Golden, Founder, Chairman and prior CEO of Noveome.
Mr. Velis added, “I’m proud to join Noveome as CEO. It’s a very innovative company with next generation therapeutic applications such as traumatic brain injury and COVID-19. I intend to apply my leadership experience to guide the Company, advance commercialization, and get therapies to patients in need as quickly and safely as possible.”
Mr. Velis, who has pioneered some of the most innovative medical technologies brought to market, brings extensive entrepreneurial and venture capital experience to Noveome. He is the Founder and Executive Chairman of Miraki Innovation, where he forecasts global health and medical challenges, uncovers innovative technologies and assembles teams of industry experts to build companies that solve these global problems. He brings a differentiated approach to venture investing through entrepreneurial science. Auris Health is one of several ventures founded, grown or brought to exit by Mr. Velis’ leadership. Chris has set the gold standard for motion preservation, regeneration of cartilage and soft tissue through the use of novel peptides, tissue regeneration using DNA pairs, and stem cell and PRP technologies for use in regenerative medicine. Throughout his 27-year career, Mr. Velis has also represented more than 150 medical device companies in a variety of business transactions. He is now focused on revolutionizing the way we battle infectious disease, greater advancements in surgical robotics, and bringing technologies that optimize human performance to the world.
Mr. Velis graduated from the University of Massachusetts Amherst with a Bachelor of Arts in Economics and earned a Master of Business from the Questrom School of Business at Boston University. He has given talks at the Hamlyn Symposium on Medical Robotics, China’s Global Innovation and Entrepreneurship Fair, the U.A.E.’s Innovation Week, Massachusetts General Hospital’s Biotech Funding Panel, LSI’s Emerging MedTech Summit, and Harvard University’s Medical and Kennedy Schools. He has been featured on NBC10, the Wall Street Journal, Boston Business Journal and PE Hub. Companies he has founded have won numerous awards including MedTech Insight Award for Best Technological Innovation, CNBC Disrupter 50, Acquisition International Finance Award for Best Medical Technology VC Firm and Corporate LiveWire M&A Award for Health & Medical Technology Consultancy of the Year.
About Noveome Biotherapeutics, Inc.
Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects (PEDs). ST266 is also being evaluated in a Phase 1 open-label clinical trial to establish the safety of ST266 in intranasal transcribriform delivery from nose-to-brain and eye. The company is actively planning a follow-up clinical study to further characterize the efficacy and safety of ST266 for the treatment of PEDs and has initiated a Phase 1 study evaluating the safety of intravenously administered ST266 in COVID-19 patients. For more information, visit www.noveome.com.
Contacts
Erik Clausen
CG Life for Noveome Biotherapeutics, Inc.
781-608-7091
noveome@cglife.com
